Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017

News Archive

Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017

 

Enanta Announces Data to be Presented on AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) at The Liver Meeting® 2017

 

Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017

 

Enanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C

 

Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors

 

Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors

 

Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors

 

Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences

WATERTOWN, Mass.–(BUSINESS WIRE)–Aug. 30, 2017– Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at each of the following investor conferences:

  • September 6, 9:05 a.m. ET – Baird 2017 Global Healthcare Conference, New York City
  • September 13, 1:35 p.m. ET – Morgan Stanley 15th Annual Global Healthcare Conference, New York City
  • September 25, 8:00 a.m. ET – Cantor Fitzgerald Global Healthcare Conference, New York City

A live webcast and replay of each presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. The webcast replay will be available following each presentation and will be archived for approximately 30 days.

About Enanta
Enanta Pharmaceuticals has used its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, paritaprevir and glecaprevir, discovered and developed through Enanta’s collaboration with AbbVie, have now been approved by the FDA as part of AbbVie’s direct-acting antiviral (DAA) regimens, MAVYRET™ (glecaprevir/pibrentasvir) and VIEKIRA PAK® (paritaprevir/ritonavir/ombitasvir/dasabuvir), for the treatment of hepatitis C virus (HCV).

Royalties and milestone payments from the AbbVie collaboration are helping to fund Enanta’s research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.

Source: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com

 

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017

 

Enanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in as Little as 8 Weeks